Medical Care
Global Respiratory Antivirals Market Research Report 2025
- Jul 08, 25
- ID: 347742
- Pages: 84
- Figures: 88
- Views: 1
The global market for Respiratory Antivirals was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Respiratory Antivirals, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Respiratory Antivirals.
The Respiratory Antivirals market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Respiratory Antivirals market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Respiratory Antivirals companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
Boehringer Ingelheim
AstraZeneca
Merck
Novartis
Beximco Pharmaceuticals
Pfizer
Roche
Bristol-Myers Squibb Company
Johnson & Johnson
AbbVie Inc.
Sanofi
Segment by Type
Nucleoside Analogs
Neuraminidase Inhibitors
Ion Channel Blockers
Fusion Protein Inhibitors
Segment by Application
Upper Respiratory Tract Infections (URTIs)
Influenza
Bronchiolitis
Pneumonia
Measles
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Respiratory Antivirals company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Respiratory Antivirals, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Respiratory Antivirals.
The Respiratory Antivirals market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Respiratory Antivirals market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Respiratory Antivirals companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
Boehringer Ingelheim
AstraZeneca
Merck
Novartis
Beximco Pharmaceuticals
Pfizer
Roche
Bristol-Myers Squibb Company
Johnson & Johnson
AbbVie Inc.
Sanofi
Segment by Type
Nucleoside Analogs
Neuraminidase Inhibitors
Ion Channel Blockers
Fusion Protein Inhibitors
Segment by Application
Upper Respiratory Tract Infections (URTIs)
Influenza
Bronchiolitis
Pneumonia
Measles
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Respiratory Antivirals company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Respiratory Antivirals Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Nucleoside Analogs
1.2.3 Neuraminidase Inhibitors
1.2.4 Ion Channel Blockers
1.2.5 Fusion Protein Inhibitors
1.3 Market by Application
1.3.1 Global Respiratory Antivirals Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Upper Respiratory Tract Infections (URTIs)
1.3.3 Influenza
1.3.4 Bronchiolitis
1.3.5 Pneumonia
1.3.6 Measles
1.3.7 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Respiratory Antivirals Market Perspective (2020-2031)
2.2 Global Respiratory Antivirals Growth Trends by Region
2.2.1 Global Respiratory Antivirals Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Respiratory Antivirals Historic Market Size by Region (2020-2025)
2.2.3 Respiratory Antivirals Forecasted Market Size by Region (2026-2031)
2.3 Respiratory Antivirals Market Dynamics
2.3.1 Respiratory Antivirals Industry Trends
2.3.2 Respiratory Antivirals Market Drivers
2.3.3 Respiratory Antivirals Market Challenges
2.3.4 Respiratory Antivirals Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Respiratory Antivirals Players by Revenue
3.1.1 Global Top Respiratory Antivirals Players by Revenue (2020-2025)
3.1.2 Global Respiratory Antivirals Revenue Market Share by Players (2020-2025)
3.2 Global Respiratory Antivirals Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Respiratory Antivirals Revenue
3.4 Global Respiratory Antivirals Market Concentration Ratio
3.4.1 Global Respiratory Antivirals Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Respiratory Antivirals Revenue in 2024
3.5 Global Key Players of Respiratory Antivirals Head office and Area Served
3.6 Global Key Players of Respiratory Antivirals, Product and Application
3.7 Global Key Players of Respiratory Antivirals, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Respiratory Antivirals Breakdown Data by Type
4.1 Global Respiratory Antivirals Historic Market Size by Type (2020-2025)
4.2 Global Respiratory Antivirals Forecasted Market Size by Type (2026-2031)
5 Respiratory Antivirals Breakdown Data by Application
5.1 Global Respiratory Antivirals Historic Market Size by Application (2020-2025)
5.2 Global Respiratory Antivirals Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Respiratory Antivirals Market Size (2020-2031)
6.2 North America Respiratory Antivirals Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Respiratory Antivirals Market Size by Country (2020-2025)
6.4 North America Respiratory Antivirals Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Respiratory Antivirals Market Size (2020-2031)
7.2 Europe Respiratory Antivirals Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Respiratory Antivirals Market Size by Country (2020-2025)
7.4 Europe Respiratory Antivirals Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Respiratory Antivirals Market Size (2020-2031)
8.2 Asia-Pacific Respiratory Antivirals Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Respiratory Antivirals Market Size by Region (2020-2025)
8.4 Asia-Pacific Respiratory Antivirals Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Respiratory Antivirals Market Size (2020-2031)
9.2 Latin America Respiratory Antivirals Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Respiratory Antivirals Market Size by Country (2020-2025)
9.4 Latin America Respiratory Antivirals Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Respiratory Antivirals Market Size (2020-2031)
10.2 Middle East & Africa Respiratory Antivirals Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Respiratory Antivirals Market Size by Country (2020-2025)
10.4 Middle East & Africa Respiratory Antivirals Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Details
11.1.2 GSK Business Overview
11.1.3 GSK Respiratory Antivirals Introduction
11.1.4 GSK Revenue in Respiratory Antivirals Business (2020-2025)
11.1.5 GSK Recent Development
11.2 Boehringer Ingelheim
11.2.1 Boehringer Ingelheim Company Details
11.2.2 Boehringer Ingelheim Business Overview
11.2.3 Boehringer Ingelheim Respiratory Antivirals Introduction
11.2.4 Boehringer Ingelheim Revenue in Respiratory Antivirals Business (2020-2025)
11.2.5 Boehringer Ingelheim Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Details
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Respiratory Antivirals Introduction
11.3.4 AstraZeneca Revenue in Respiratory Antivirals Business (2020-2025)
11.3.5 AstraZeneca Recent Development
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Merck Business Overview
11.4.3 Merck Respiratory Antivirals Introduction
11.4.4 Merck Revenue in Respiratory Antivirals Business (2020-2025)
11.4.5 Merck Recent Development
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Novartis Business Overview
11.5.3 Novartis Respiratory Antivirals Introduction
11.5.4 Novartis Revenue in Respiratory Antivirals Business (2020-2025)
11.5.5 Novartis Recent Development
11.6 Beximco Pharmaceuticals
11.6.1 Beximco Pharmaceuticals Company Details
11.6.2 Beximco Pharmaceuticals Business Overview
11.6.3 Beximco Pharmaceuticals Respiratory Antivirals Introduction
11.6.4 Beximco Pharmaceuticals Revenue in Respiratory Antivirals Business (2020-2025)
11.6.5 Beximco Pharmaceuticals Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Details
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Respiratory Antivirals Introduction
11.7.4 Pfizer Revenue in Respiratory Antivirals Business (2020-2025)
11.7.5 Pfizer Recent Development
11.8 Roche
11.8.1 Roche Company Details
11.8.2 Roche Business Overview
11.8.3 Roche Respiratory Antivirals Introduction
11.8.4 Roche Revenue in Respiratory Antivirals Business (2020-2025)
11.8.5 Roche Recent Development
11.9 Bristol-Myers Squibb Company
11.9.1 Bristol-Myers Squibb Company Company Details
11.9.2 Bristol-Myers Squibb Company Business Overview
11.9.3 Bristol-Myers Squibb Company Respiratory Antivirals Introduction
11.9.4 Bristol-Myers Squibb Company Revenue in Respiratory Antivirals Business (2020-2025)
11.9.5 Bristol-Myers Squibb Company Recent Development
11.10 Johnson & Johnson
11.10.1 Johnson & Johnson Company Details
11.10.2 Johnson & Johnson Business Overview
11.10.3 Johnson & Johnson Respiratory Antivirals Introduction
11.10.4 Johnson & Johnson Revenue in Respiratory Antivirals Business (2020-2025)
11.10.5 Johnson & Johnson Recent Development
11.11 AbbVie Inc.
11.11.1 AbbVie Inc. Company Details
11.11.2 AbbVie Inc. Business Overview
11.11.3 AbbVie Inc. Respiratory Antivirals Introduction
11.11.4 AbbVie Inc. Revenue in Respiratory Antivirals Business (2020-2025)
11.11.5 AbbVie Inc. Recent Development
11.12 Sanofi
11.12.1 Sanofi Company Details
11.12.2 Sanofi Business Overview
11.12.3 Sanofi Respiratory Antivirals Introduction
11.12.4 Sanofi Revenue in Respiratory Antivirals Business (2020-2025)
11.12.5 Sanofi Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Respiratory Antivirals Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Nucleoside Analogs
1.2.3 Neuraminidase Inhibitors
1.2.4 Ion Channel Blockers
1.2.5 Fusion Protein Inhibitors
1.3 Market by Application
1.3.1 Global Respiratory Antivirals Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Upper Respiratory Tract Infections (URTIs)
1.3.3 Influenza
1.3.4 Bronchiolitis
1.3.5 Pneumonia
1.3.6 Measles
1.3.7 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Respiratory Antivirals Market Perspective (2020-2031)
2.2 Global Respiratory Antivirals Growth Trends by Region
2.2.1 Global Respiratory Antivirals Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Respiratory Antivirals Historic Market Size by Region (2020-2025)
2.2.3 Respiratory Antivirals Forecasted Market Size by Region (2026-2031)
2.3 Respiratory Antivirals Market Dynamics
2.3.1 Respiratory Antivirals Industry Trends
2.3.2 Respiratory Antivirals Market Drivers
2.3.3 Respiratory Antivirals Market Challenges
2.3.4 Respiratory Antivirals Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Respiratory Antivirals Players by Revenue
3.1.1 Global Top Respiratory Antivirals Players by Revenue (2020-2025)
3.1.2 Global Respiratory Antivirals Revenue Market Share by Players (2020-2025)
3.2 Global Respiratory Antivirals Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Respiratory Antivirals Revenue
3.4 Global Respiratory Antivirals Market Concentration Ratio
3.4.1 Global Respiratory Antivirals Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Respiratory Antivirals Revenue in 2024
3.5 Global Key Players of Respiratory Antivirals Head office and Area Served
3.6 Global Key Players of Respiratory Antivirals, Product and Application
3.7 Global Key Players of Respiratory Antivirals, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Respiratory Antivirals Breakdown Data by Type
4.1 Global Respiratory Antivirals Historic Market Size by Type (2020-2025)
4.2 Global Respiratory Antivirals Forecasted Market Size by Type (2026-2031)
5 Respiratory Antivirals Breakdown Data by Application
5.1 Global Respiratory Antivirals Historic Market Size by Application (2020-2025)
5.2 Global Respiratory Antivirals Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Respiratory Antivirals Market Size (2020-2031)
6.2 North America Respiratory Antivirals Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Respiratory Antivirals Market Size by Country (2020-2025)
6.4 North America Respiratory Antivirals Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Respiratory Antivirals Market Size (2020-2031)
7.2 Europe Respiratory Antivirals Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Respiratory Antivirals Market Size by Country (2020-2025)
7.4 Europe Respiratory Antivirals Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Respiratory Antivirals Market Size (2020-2031)
8.2 Asia-Pacific Respiratory Antivirals Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Respiratory Antivirals Market Size by Region (2020-2025)
8.4 Asia-Pacific Respiratory Antivirals Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Respiratory Antivirals Market Size (2020-2031)
9.2 Latin America Respiratory Antivirals Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Respiratory Antivirals Market Size by Country (2020-2025)
9.4 Latin America Respiratory Antivirals Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Respiratory Antivirals Market Size (2020-2031)
10.2 Middle East & Africa Respiratory Antivirals Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Respiratory Antivirals Market Size by Country (2020-2025)
10.4 Middle East & Africa Respiratory Antivirals Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Details
11.1.2 GSK Business Overview
11.1.3 GSK Respiratory Antivirals Introduction
11.1.4 GSK Revenue in Respiratory Antivirals Business (2020-2025)
11.1.5 GSK Recent Development
11.2 Boehringer Ingelheim
11.2.1 Boehringer Ingelheim Company Details
11.2.2 Boehringer Ingelheim Business Overview
11.2.3 Boehringer Ingelheim Respiratory Antivirals Introduction
11.2.4 Boehringer Ingelheim Revenue in Respiratory Antivirals Business (2020-2025)
11.2.5 Boehringer Ingelheim Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Details
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Respiratory Antivirals Introduction
11.3.4 AstraZeneca Revenue in Respiratory Antivirals Business (2020-2025)
11.3.5 AstraZeneca Recent Development
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Merck Business Overview
11.4.3 Merck Respiratory Antivirals Introduction
11.4.4 Merck Revenue in Respiratory Antivirals Business (2020-2025)
11.4.5 Merck Recent Development
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Novartis Business Overview
11.5.3 Novartis Respiratory Antivirals Introduction
11.5.4 Novartis Revenue in Respiratory Antivirals Business (2020-2025)
11.5.5 Novartis Recent Development
11.6 Beximco Pharmaceuticals
11.6.1 Beximco Pharmaceuticals Company Details
11.6.2 Beximco Pharmaceuticals Business Overview
11.6.3 Beximco Pharmaceuticals Respiratory Antivirals Introduction
11.6.4 Beximco Pharmaceuticals Revenue in Respiratory Antivirals Business (2020-2025)
11.6.5 Beximco Pharmaceuticals Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Details
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Respiratory Antivirals Introduction
11.7.4 Pfizer Revenue in Respiratory Antivirals Business (2020-2025)
11.7.5 Pfizer Recent Development
11.8 Roche
11.8.1 Roche Company Details
11.8.2 Roche Business Overview
11.8.3 Roche Respiratory Antivirals Introduction
11.8.4 Roche Revenue in Respiratory Antivirals Business (2020-2025)
11.8.5 Roche Recent Development
11.9 Bristol-Myers Squibb Company
11.9.1 Bristol-Myers Squibb Company Company Details
11.9.2 Bristol-Myers Squibb Company Business Overview
11.9.3 Bristol-Myers Squibb Company Respiratory Antivirals Introduction
11.9.4 Bristol-Myers Squibb Company Revenue in Respiratory Antivirals Business (2020-2025)
11.9.5 Bristol-Myers Squibb Company Recent Development
11.10 Johnson & Johnson
11.10.1 Johnson & Johnson Company Details
11.10.2 Johnson & Johnson Business Overview
11.10.3 Johnson & Johnson Respiratory Antivirals Introduction
11.10.4 Johnson & Johnson Revenue in Respiratory Antivirals Business (2020-2025)
11.10.5 Johnson & Johnson Recent Development
11.11 AbbVie Inc.
11.11.1 AbbVie Inc. Company Details
11.11.2 AbbVie Inc. Business Overview
11.11.3 AbbVie Inc. Respiratory Antivirals Introduction
11.11.4 AbbVie Inc. Revenue in Respiratory Antivirals Business (2020-2025)
11.11.5 AbbVie Inc. Recent Development
11.12 Sanofi
11.12.1 Sanofi Company Details
11.12.2 Sanofi Business Overview
11.12.3 Sanofi Respiratory Antivirals Introduction
11.12.4 Sanofi Revenue in Respiratory Antivirals Business (2020-2025)
11.12.5 Sanofi Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Respiratory Antivirals Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Nucleoside Analogs
Table 3. Key Players of Neuraminidase Inhibitors
Table 4. Key Players of Ion Channel Blockers
Table 5. Key Players of Fusion Protein Inhibitors
Table 6. Global Respiratory Antivirals Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Respiratory Antivirals Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Respiratory Antivirals Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Respiratory Antivirals Market Share by Region (2020-2025)
Table 10. Global Respiratory Antivirals Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Respiratory Antivirals Market Share by Region (2026-2031)
Table 12. Respiratory Antivirals Market Trends
Table 13. Respiratory Antivirals Market Drivers
Table 14. Respiratory Antivirals Market Challenges
Table 15. Respiratory Antivirals Market Restraints
Table 16. Global Respiratory Antivirals Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Respiratory Antivirals Market Share by Players (2020-2025)
Table 18. Global Top Respiratory Antivirals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Respiratory Antivirals as of 2024)
Table 19. Ranking of Global Top Respiratory Antivirals Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Respiratory Antivirals Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Respiratory Antivirals, Headquarters and Area Served
Table 22. Global Key Players of Respiratory Antivirals, Product and Application
Table 23. Global Key Players of Respiratory Antivirals, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Respiratory Antivirals Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Respiratory Antivirals Revenue Market Share by Type (2020-2025)
Table 27. Global Respiratory Antivirals Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Respiratory Antivirals Revenue Market Share by Type (2026-2031)
Table 29. Global Respiratory Antivirals Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Respiratory Antivirals Revenue Market Share by Application (2020-2025)
Table 31. Global Respiratory Antivirals Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Respiratory Antivirals Revenue Market Share by Application (2026-2031)
Table 33. North America Respiratory Antivirals Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Respiratory Antivirals Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Respiratory Antivirals Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Respiratory Antivirals Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Respiratory Antivirals Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Respiratory Antivirals Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Respiratory Antivirals Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Respiratory Antivirals Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Respiratory Antivirals Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Respiratory Antivirals Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Respiratory Antivirals Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Respiratory Antivirals Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Respiratory Antivirals Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Respiratory Antivirals Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Respiratory Antivirals Market Size by Country (2026-2031) & (US$ Million)
Table 48. GSK Company Details
Table 49. GSK Business Overview
Table 50. GSK Respiratory Antivirals Product
Table 51. GSK Revenue in Respiratory Antivirals Business (2020-2025) & (US$ Million)
Table 52. GSK Recent Development
Table 53. Boehringer Ingelheim Company Details
Table 54. Boehringer Ingelheim Business Overview
Table 55. Boehringer Ingelheim Respiratory Antivirals Product
Table 56. Boehringer Ingelheim Revenue in Respiratory Antivirals Business (2020-2025) & (US$ Million)
Table 57. Boehringer Ingelheim Recent Development
Table 58. AstraZeneca Company Details
Table 59. AstraZeneca Business Overview
Table 60. AstraZeneca Respiratory Antivirals Product
Table 61. AstraZeneca Revenue in Respiratory Antivirals Business (2020-2025) & (US$ Million)
Table 62. AstraZeneca Recent Development
Table 63. Merck Company Details
Table 64. Merck Business Overview
Table 65. Merck Respiratory Antivirals Product
Table 66. Merck Revenue in Respiratory Antivirals Business (2020-2025) & (US$ Million)
Table 67. Merck Recent Development
Table 68. Novartis Company Details
Table 69. Novartis Business Overview
Table 70. Novartis Respiratory Antivirals Product
Table 71. Novartis Revenue in Respiratory Antivirals Business (2020-2025) & (US$ Million)
Table 72. Novartis Recent Development
Table 73. Beximco Pharmaceuticals Company Details
Table 74. Beximco Pharmaceuticals Business Overview
Table 75. Beximco Pharmaceuticals Respiratory Antivirals Product
Table 76. Beximco Pharmaceuticals Revenue in Respiratory Antivirals Business (2020-2025) & (US$ Million)
Table 77. Beximco Pharmaceuticals Recent Development
Table 78. Pfizer Company Details
Table 79. Pfizer Business Overview
Table 80. Pfizer Respiratory Antivirals Product
Table 81. Pfizer Revenue in Respiratory Antivirals Business (2020-2025) & (US$ Million)
Table 82. Pfizer Recent Development
Table 83. Roche Company Details
Table 84. Roche Business Overview
Table 85. Roche Respiratory Antivirals Product
Table 86. Roche Revenue in Respiratory Antivirals Business (2020-2025) & (US$ Million)
Table 87. Roche Recent Development
Table 88. Bristol-Myers Squibb Company Company Details
Table 89. Bristol-Myers Squibb Company Business Overview
Table 90. Bristol-Myers Squibb Company Respiratory Antivirals Product
Table 91. Bristol-Myers Squibb Company Revenue in Respiratory Antivirals Business (2020-2025) & (US$ Million)
Table 92. Bristol-Myers Squibb Company Recent Development
Table 93. Johnson & Johnson Company Details
Table 94. Johnson & Johnson Business Overview
Table 95. Johnson & Johnson Respiratory Antivirals Product
Table 96. Johnson & Johnson Revenue in Respiratory Antivirals Business (2020-2025) & (US$ Million)
Table 97. Johnson & Johnson Recent Development
Table 98. AbbVie Inc. Company Details
Table 99. AbbVie Inc. Business Overview
Table 100. AbbVie Inc. Respiratory Antivirals Product
Table 101. AbbVie Inc. Revenue in Respiratory Antivirals Business (2020-2025) & (US$ Million)
Table 102. AbbVie Inc. Recent Development
Table 103. Sanofi Company Details
Table 104. Sanofi Business Overview
Table 105. Sanofi Respiratory Antivirals Product
Table 106. Sanofi Revenue in Respiratory Antivirals Business (2020-2025) & (US$ Million)
Table 107. Sanofi Recent Development
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
Table 111. Authors List of This Report
List of Figures
Figure 1. Respiratory Antivirals Picture
Figure 2. Global Respiratory Antivirals Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Respiratory Antivirals Market Share by Type: 2024 VS 2031
Figure 4. Nucleoside Analogs Features
Figure 5. Neuraminidase Inhibitors Features
Figure 6. Ion Channel Blockers Features
Figure 7. Fusion Protein Inhibitors Features
Figure 8. Global Respiratory Antivirals Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Respiratory Antivirals Market Share by Application: 2024 VS 2031
Figure 10. Upper Respiratory Tract Infections (URTIs) Case Studies
Figure 11. Influenza Case Studies
Figure 12. Bronchiolitis Case Studies
Figure 13. Pneumonia Case Studies
Figure 14. Measles Case Studies
Figure 15. Others Case Studies
Figure 16. Respiratory Antivirals Report Years Considered
Figure 17. Global Respiratory Antivirals Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 18. Global Respiratory Antivirals Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 19. Global Respiratory Antivirals Market Share by Region: 2024 VS 2031
Figure 20. Global Respiratory Antivirals Market Share by Players in 2024
Figure 21. Global Top Respiratory Antivirals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Respiratory Antivirals as of 2024)
Figure 22. The Top 10 and 5 Players Market Share by Respiratory Antivirals Revenue in 2024
Figure 23. North America Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. North America Respiratory Antivirals Market Share by Country (2020-2031)
Figure 25. United States Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Canada Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Europe Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Europe Respiratory Antivirals Market Share by Country (2020-2031)
Figure 29. Germany Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. France Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. U.K. Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Italy Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Russia Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Nordic Countries Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Respiratory Antivirals Market Share by Region (2020-2031)
Figure 37. China Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Japan Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. South Korea Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Southeast Asia Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. India Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Australia Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Latin America Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Latin America Respiratory Antivirals Market Share by Country (2020-2031)
Figure 45. Mexico Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Brazil Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Middle East & Africa Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Middle East & Africa Respiratory Antivirals Market Share by Country (2020-2031)
Figure 49. Turkey Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Saudi Arabia Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. UAE Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. GSK Revenue Growth Rate in Respiratory Antivirals Business (2020-2025)
Figure 53. Boehringer Ingelheim Revenue Growth Rate in Respiratory Antivirals Business (2020-2025)
Figure 54. AstraZeneca Revenue Growth Rate in Respiratory Antivirals Business (2020-2025)
Figure 55. Merck Revenue Growth Rate in Respiratory Antivirals Business (2020-2025)
Figure 56. Novartis Revenue Growth Rate in Respiratory Antivirals Business (2020-2025)
Figure 57. Beximco Pharmaceuticals Revenue Growth Rate in Respiratory Antivirals Business (2020-2025)
Figure 58. Pfizer Revenue Growth Rate in Respiratory Antivirals Business (2020-2025)
Figure 59. Roche Revenue Growth Rate in Respiratory Antivirals Business (2020-2025)
Figure 60. Bristol-Myers Squibb Company Revenue Growth Rate in Respiratory Antivirals Business (2020-2025)
Figure 61. Johnson & Johnson Revenue Growth Rate in Respiratory Antivirals Business (2020-2025)
Figure 62. AbbVie Inc. Revenue Growth Rate in Respiratory Antivirals Business (2020-2025)
Figure 63. Sanofi Revenue Growth Rate in Respiratory Antivirals Business (2020-2025)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Table 1. Global Respiratory Antivirals Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Nucleoside Analogs
Table 3. Key Players of Neuraminidase Inhibitors
Table 4. Key Players of Ion Channel Blockers
Table 5. Key Players of Fusion Protein Inhibitors
Table 6. Global Respiratory Antivirals Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Respiratory Antivirals Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Respiratory Antivirals Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Respiratory Antivirals Market Share by Region (2020-2025)
Table 10. Global Respiratory Antivirals Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Respiratory Antivirals Market Share by Region (2026-2031)
Table 12. Respiratory Antivirals Market Trends
Table 13. Respiratory Antivirals Market Drivers
Table 14. Respiratory Antivirals Market Challenges
Table 15. Respiratory Antivirals Market Restraints
Table 16. Global Respiratory Antivirals Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Respiratory Antivirals Market Share by Players (2020-2025)
Table 18. Global Top Respiratory Antivirals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Respiratory Antivirals as of 2024)
Table 19. Ranking of Global Top Respiratory Antivirals Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Respiratory Antivirals Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Respiratory Antivirals, Headquarters and Area Served
Table 22. Global Key Players of Respiratory Antivirals, Product and Application
Table 23. Global Key Players of Respiratory Antivirals, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Respiratory Antivirals Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Respiratory Antivirals Revenue Market Share by Type (2020-2025)
Table 27. Global Respiratory Antivirals Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Respiratory Antivirals Revenue Market Share by Type (2026-2031)
Table 29. Global Respiratory Antivirals Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Respiratory Antivirals Revenue Market Share by Application (2020-2025)
Table 31. Global Respiratory Antivirals Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Respiratory Antivirals Revenue Market Share by Application (2026-2031)
Table 33. North America Respiratory Antivirals Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Respiratory Antivirals Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Respiratory Antivirals Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Respiratory Antivirals Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Respiratory Antivirals Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Respiratory Antivirals Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Respiratory Antivirals Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Respiratory Antivirals Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Respiratory Antivirals Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Respiratory Antivirals Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Respiratory Antivirals Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Respiratory Antivirals Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Respiratory Antivirals Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Respiratory Antivirals Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Respiratory Antivirals Market Size by Country (2026-2031) & (US$ Million)
Table 48. GSK Company Details
Table 49. GSK Business Overview
Table 50. GSK Respiratory Antivirals Product
Table 51. GSK Revenue in Respiratory Antivirals Business (2020-2025) & (US$ Million)
Table 52. GSK Recent Development
Table 53. Boehringer Ingelheim Company Details
Table 54. Boehringer Ingelheim Business Overview
Table 55. Boehringer Ingelheim Respiratory Antivirals Product
Table 56. Boehringer Ingelheim Revenue in Respiratory Antivirals Business (2020-2025) & (US$ Million)
Table 57. Boehringer Ingelheim Recent Development
Table 58. AstraZeneca Company Details
Table 59. AstraZeneca Business Overview
Table 60. AstraZeneca Respiratory Antivirals Product
Table 61. AstraZeneca Revenue in Respiratory Antivirals Business (2020-2025) & (US$ Million)
Table 62. AstraZeneca Recent Development
Table 63. Merck Company Details
Table 64. Merck Business Overview
Table 65. Merck Respiratory Antivirals Product
Table 66. Merck Revenue in Respiratory Antivirals Business (2020-2025) & (US$ Million)
Table 67. Merck Recent Development
Table 68. Novartis Company Details
Table 69. Novartis Business Overview
Table 70. Novartis Respiratory Antivirals Product
Table 71. Novartis Revenue in Respiratory Antivirals Business (2020-2025) & (US$ Million)
Table 72. Novartis Recent Development
Table 73. Beximco Pharmaceuticals Company Details
Table 74. Beximco Pharmaceuticals Business Overview
Table 75. Beximco Pharmaceuticals Respiratory Antivirals Product
Table 76. Beximco Pharmaceuticals Revenue in Respiratory Antivirals Business (2020-2025) & (US$ Million)
Table 77. Beximco Pharmaceuticals Recent Development
Table 78. Pfizer Company Details
Table 79. Pfizer Business Overview
Table 80. Pfizer Respiratory Antivirals Product
Table 81. Pfizer Revenue in Respiratory Antivirals Business (2020-2025) & (US$ Million)
Table 82. Pfizer Recent Development
Table 83. Roche Company Details
Table 84. Roche Business Overview
Table 85. Roche Respiratory Antivirals Product
Table 86. Roche Revenue in Respiratory Antivirals Business (2020-2025) & (US$ Million)
Table 87. Roche Recent Development
Table 88. Bristol-Myers Squibb Company Company Details
Table 89. Bristol-Myers Squibb Company Business Overview
Table 90. Bristol-Myers Squibb Company Respiratory Antivirals Product
Table 91. Bristol-Myers Squibb Company Revenue in Respiratory Antivirals Business (2020-2025) & (US$ Million)
Table 92. Bristol-Myers Squibb Company Recent Development
Table 93. Johnson & Johnson Company Details
Table 94. Johnson & Johnson Business Overview
Table 95. Johnson & Johnson Respiratory Antivirals Product
Table 96. Johnson & Johnson Revenue in Respiratory Antivirals Business (2020-2025) & (US$ Million)
Table 97. Johnson & Johnson Recent Development
Table 98. AbbVie Inc. Company Details
Table 99. AbbVie Inc. Business Overview
Table 100. AbbVie Inc. Respiratory Antivirals Product
Table 101. AbbVie Inc. Revenue in Respiratory Antivirals Business (2020-2025) & (US$ Million)
Table 102. AbbVie Inc. Recent Development
Table 103. Sanofi Company Details
Table 104. Sanofi Business Overview
Table 105. Sanofi Respiratory Antivirals Product
Table 106. Sanofi Revenue in Respiratory Antivirals Business (2020-2025) & (US$ Million)
Table 107. Sanofi Recent Development
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
Table 111. Authors List of This Report
List of Figures
Figure 1. Respiratory Antivirals Picture
Figure 2. Global Respiratory Antivirals Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Respiratory Antivirals Market Share by Type: 2024 VS 2031
Figure 4. Nucleoside Analogs Features
Figure 5. Neuraminidase Inhibitors Features
Figure 6. Ion Channel Blockers Features
Figure 7. Fusion Protein Inhibitors Features
Figure 8. Global Respiratory Antivirals Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Respiratory Antivirals Market Share by Application: 2024 VS 2031
Figure 10. Upper Respiratory Tract Infections (URTIs) Case Studies
Figure 11. Influenza Case Studies
Figure 12. Bronchiolitis Case Studies
Figure 13. Pneumonia Case Studies
Figure 14. Measles Case Studies
Figure 15. Others Case Studies
Figure 16. Respiratory Antivirals Report Years Considered
Figure 17. Global Respiratory Antivirals Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 18. Global Respiratory Antivirals Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 19. Global Respiratory Antivirals Market Share by Region: 2024 VS 2031
Figure 20. Global Respiratory Antivirals Market Share by Players in 2024
Figure 21. Global Top Respiratory Antivirals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Respiratory Antivirals as of 2024)
Figure 22. The Top 10 and 5 Players Market Share by Respiratory Antivirals Revenue in 2024
Figure 23. North America Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. North America Respiratory Antivirals Market Share by Country (2020-2031)
Figure 25. United States Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Canada Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Europe Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Europe Respiratory Antivirals Market Share by Country (2020-2031)
Figure 29. Germany Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. France Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. U.K. Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Italy Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Russia Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Nordic Countries Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Respiratory Antivirals Market Share by Region (2020-2031)
Figure 37. China Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Japan Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. South Korea Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Southeast Asia Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. India Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Australia Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Latin America Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Latin America Respiratory Antivirals Market Share by Country (2020-2031)
Figure 45. Mexico Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Brazil Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Middle East & Africa Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Middle East & Africa Respiratory Antivirals Market Share by Country (2020-2031)
Figure 49. Turkey Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Saudi Arabia Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. UAE Respiratory Antivirals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. GSK Revenue Growth Rate in Respiratory Antivirals Business (2020-2025)
Figure 53. Boehringer Ingelheim Revenue Growth Rate in Respiratory Antivirals Business (2020-2025)
Figure 54. AstraZeneca Revenue Growth Rate in Respiratory Antivirals Business (2020-2025)
Figure 55. Merck Revenue Growth Rate in Respiratory Antivirals Business (2020-2025)
Figure 56. Novartis Revenue Growth Rate in Respiratory Antivirals Business (2020-2025)
Figure 57. Beximco Pharmaceuticals Revenue Growth Rate in Respiratory Antivirals Business (2020-2025)
Figure 58. Pfizer Revenue Growth Rate in Respiratory Antivirals Business (2020-2025)
Figure 59. Roche Revenue Growth Rate in Respiratory Antivirals Business (2020-2025)
Figure 60. Bristol-Myers Squibb Company Revenue Growth Rate in Respiratory Antivirals Business (2020-2025)
Figure 61. Johnson & Johnson Revenue Growth Rate in Respiratory Antivirals Business (2020-2025)
Figure 62. AbbVie Inc. Revenue Growth Rate in Respiratory Antivirals Business (2020-2025)
Figure 63. Sanofi Revenue Growth Rate in Respiratory Antivirals Business (2020-2025)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Electrolytes for Lithium-Ion Batteries Market Research Report 2025
Jul 14, 25
Global Vanadium Products Market Research Report 2025
Jul 14, 25
Global High-purity Vanadium Oxide Market Research Report 2025
Jul 14, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232